⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Targeted Drug Delivery Market Size, Share, Trends, and Global Forecast, 2026-2036 | $57.5 Billion Opportunity Fueled by ADCs, LNPs, and 16.5% CAGR
globenewswire.com
PFE
GILD
ABBV
JNJ
ALNY
ARWR
IONS
MRNA
BNTX
HALO
ADCT
AZN
REGN
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO ® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
businesswire.com
ARWR
Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM
globenewswire.com
ARWR
Acute Myocardial Infarction (AMI) - Market Insights, Epidemiology, and Market Forecast Now Available; Acute Myocardial Infarction (AMI) Market Projected to Reach Approximately USD 6.00 Billion by 2036
globenewswire.com
AMGN
MRK
REGN
AZN
PFE
BMY
JNJ
VTRS
CELC
NVO
ARWR
China RNA Delivery Technologies Market by RNA Type, Platform, Application, End User, and Company Size, Forecast to 2035 | 18.8% CAGR Driven by LNP and mRNA Expansion
globenewswire.com
ARWR
MRNA
BNTX
ABBV
LULU
EL
LLY
CAN
Atherosclerotic Cardiovascular Disease (ASCVD) Market Insights, Epidemiology, and Forecast - 2036 | 7MM Market to Reach USD 40 Billion as Precision Therapies Reshape Growth
globenewswire.com
AMGN
ARWR
NVS
ALNY
SNY
REGN
ESPR
JNJ
AZN
AMRN
MRK
LLY
BMY
ON
NVO
Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities
globenewswire.com
AMGN
CHRS
ARWR
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
globenewswire.com
ALNY
ARWR
SLN
BNTC
RNA Therapeutics Market Size, Share & Trends Analysis - Global Forecast to 2036
globenewswire.com
MRNA
BNTX
CVAC
ALNY
IONS
ARWR
REGN
SRPT
SLN
BEAM
NTLA
CRSP
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
globenewswire.com
ALNY
IONS
SRPT
BIIB
NVS
AZN
NVO
SNY
ARWR